GlaxoSmithKline Pharmaceuticals Limited (GSK India) has reported strong financial results for the first quarter ended June 30, 2026, driven by healthy demand across its core brands, growing acceptance of innovative therapies, and continued focus on portfolio transformation. The company posted revenue of ₹924 crore for the quarter, reflecting a 15% year-on-year growth. Profit after tax (PAT) increased 24% to ₹253 crore, while EBITDA margin stood at 32%, highlighting sustained operational strength.
The company’s General Medicines business delivered robust growth during the quarter, with its five key promoted brands outperforming the market. Leading products including Augmentin, Ceftum, and T-Bact maintained their leadership positions across their respective therapeutic segments. Strong scientific engagement with healthcare professionals, improved field execution, omnichannel initiatives, and pricing actions supported the portfolio’s performance.
GSK India also continued to strengthen its Respiratory business. Innovative therapies such as Nucala (mepolizumab) continued to benefit patients suffering from severe respiratory conditions, while Trelegy Ellipta expanded its reach through improved patient access initiatives.
The Vaccines portfolio maintained its leadership in the private paediatric vaccination market, led by Infanrix Hexa and Fluarix Tetra. The company also recorded healthy growth in adult vaccination as healthcare professionals increasingly recommended Shingrix for older adults and patients with cardiovascular and metabolic conditions, leading to wider vaccine adoption.
The Oncology business continued to gain momentum following the launch of Jemperli (dostarlimab) and Zejula (niraparib) last year. Both therapies have witnessed increasing acceptance among oncologists, expanding treatment options for women with gynaecological cancers and helping improve access to advanced cancer care across India.
Commenting on the results, Bhushan Akshikar, Managing Director, GSK India, said the company’s broad-based growth reflects the strength of its established medicines, vaccines and innovative portfolio. He added that investments in scientific engagement, technology, talent development and execution have positioned the company for sustained long-term growth while enabling it to reach more patients across the country.
The company has also strengthened its supply chain through diversified sourcing, improved planning and enhanced end-to-end visibility, reducing disruptions experienced in previous quarters. Looking ahead, GSK India is preparing to introduce new therapies, including Blenrep (belantamab mafodotin) for relapsed or refractory multiple myeloma and Arexvy, a vaccine approved for preventing respiratory syncytial virus (RSV)-related lower respiratory tract disease in eligible adults.
GlaxoSmithKline Pharmaceuticals Limited (GSK India) is a subsidiary of GSK plc, a global biopharmaceutical company focused on preventing and treating disease through science, technology and innovation. In India, the company offers a broad portfolio of prescription medicines, vaccines and specialty therapies across key therapeutic areas, including infectious diseases, respiratory care, oncology and immunology. GSK India works closely with healthcare professionals, researchers and partners to improve access to quality healthcare and bring innovative treatment options to patients across the country. The company remains committed to advancing medical science, strengthening healthcare delivery and improving patient outcomes through responsible and sustainable business practices.
